







Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

RBC (erythrocytes)

Casts

Method:Flow Digital Imaging/Microscopy

Method:Flow Digital Imaging/Microscopy

Req.No : BIL4688733

Registered on: 09-Sep-2024 / 09:38 AM Collected on: 09-Sep-2024 / 09:44 AM

:UMR1943570/ 28215753

Reported on : 09-Sep-2024 / 14:09 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

Complete Urine Examination (CUE), Urine		
Investigation	Result	Biological Reference Intervals
Physical Examination		
Colour Method:Physical	LightYellow	Straw to Yellow
Appearance Method:Physical	Clear	Clear
Chemical Examination		
Reaction and pH Method:Indicator	Acidic (5.5)	4.6-8.0
Specific gravity Method:Refractometry	1.004	1.000-1.035
Protein  Method:Protein Error of pH indicators	Negative	Negative
Glucose Method:Glucose oxidase/Peroxidase	Negative	Negative
Blood Method:Peroxidase	Negative	Negative
Ketones Method:Sodium Nitroprusside	Negative	Negative
Bilirubin Method:Diazonium salt	Negative	Negative
Leucocytes Method:Esterase reaction	Negative	Negative
Nitrites Method:Modified Griess reaction	Negative	Negative
Urobilinogen Method:Diazonium salt	Negative	Up to 1.0 mg/dl (Negative)
Microscopic Examination		
Pus cells (leukocytes)  Method:Flow Digital Imaging/Microscopy	1-2	2 - 3 /hpf
Epithelial cells  Method:Flow Digital Imaging/Microscopy	1-2	2 - 5 /hpf
3 3		

Absent

Absent

Absent

Occasional hyaline casts may be seen

**DEPARTMENT OF CLINICAL PATHOLOGY** 







TO VERIFY THE REPORT ONLINE

Name : MRS.K PAKMODE

: 42 Years / Female Age / Gender

Ref.By : SELF

Req.No : BIL4688733 TID/SID :UMR1943570/ 28215753

Registered on: 09-Sep-2024 / 09:38 AM

Collected on : 09-Sep-2024 / 09:44 AM

Reported on : 09-Sep-2024 / 14:09 PM

Reference : Arcofemi Health Care Ltd -**TEST REPORT** 

Absent Phosphate, oxalate, or urate crystals may Crystals be seen

Method:Flow Digital Imaging/Microscopy

Nil Nil Others

Method:Flow Digital Imaging/Microscopy

#### Method: Semi Quantitative test ,For CUE

Reference: Godkar Clinical Diagnosis and Management by Laboratory Methods, First South Asia edition. Product kit literature.

#### Interpretation:

The complete urinalysis provides a number of measurements which look for abnormalities in the urine. Abnormal results from this test can be indicative of a number of conditions including kidney disease, urinary tract infecation or elevated levels of substances which the body is trying to remove through the urine. A urinalysis test can help identify potential health problems even when a person is asymptomatic. All the abnormal results are to be correlated clinically.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Shruti Reddy **Consultant Pathologist** Reg No.TSMC/FMR/22656









Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Reg.No : BIL4688733

TID/SID : UMR1943570/ 28215754 Registered on : 09-Sep-2024 / 09:38 AM

Collected on : 09-Sep-2024 / 09:44 AM

Reported on : 09-Sep-2024 / 16:32 PM

Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF HEMATOPATHOLOGY**

**TEST REPORT** 

#### **Blood Grouping ABO And Rh Typing, EDTA Whole Blood**

Parameter Results

Blood Grouping (ABO) B

Rh Typing (D) Positive

Method:Hemagglutination Tube Method by Forward & Reverse Grouping

Method: Hemagglutination Tube Method by Forward & Reverse Grouping

Reference: Tulip kit literature

**Interpretation:** The ABO grouping and Rh typing test determines blood type grouping (A,B, AB, O) and the Rh factor (positive or negative). A person's blood type is based on the presence or absence of certain antigens on the surface of their red blood cells and certain antibodies in the plasma. ABO antigens are poorly expresses at birth, increase gradually in strength and become fully expressed around 1 year of age.

In case of Rh(D) - Du(weak positive) or Weak D positive, the individual must be considered as Rh positive as donor and Rh negative as recipient.

Note: Records of previous blood grouping/Rh typing not available. Please verify before transfusion.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Vikas Reddy Consultant Pathologist





:UMR1943570/ 28215754

Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Reg.No : BIL4688733

Registered on: 09-Sep-2024 / 09:38 AM
Collected on: 09-Sep-2024 / 09:44 AM
Reported on: 09-Sep-2024 / 13:46 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

#### **DEPARTMENT OF HEMATOPATHOLOGY**

#### Erythrocyte Sedimentation Rate (ESR), Whole Blood

Investigation	Observed Value	Biological Reference Intervals
ESR 1st Hour	24	<=12 mm/hour

Method:Westergren/Vesmatic

#### Complete Blood Count (CBC), EDTA Whole Blood

Investigation	Observed Value	Biological Reference Intervals
Hemoglobin	11.5	12.0-15.0 g/dL
Method:Cyanide Free Lyse Hemoglobin		
PCV/HCT	35.1	36.0-46.0 vol%
Method:Calculated		
Total RBC Count	4.21	3.80-4.80 mill /cu.mm
Method:Electrical Impedance		
MCV	83.4	83.0-101.0 fL
Method:Calculated		
MCH	27.3	27.0-32.0 pg
Method:Calculated		
MCHC	32.7	31.5-34.5 g/dL
Method:Calculated		
RDW (CV)	16.3	11.6-14.0 %
Method:Calculated		
MPV	8.1	7.0-10.0 fL
Method:Calculated		
Total WBC Count	6670	4000-10000 cells/cumm
Method:Electrical Impedance		
Platelet Count	3.40	1.50-4.10 lakhs/cumm
Method:Electrical Impedance		
Differential count		
Neutrophils	61.7	40.0-80.0 %
Method:Microscopy		
Lymphocytes	25.5	20.0-40.0 %
Method:Microscopy		
Eosinophils	4.0	1.0-6.0 %
Monocytes	8.5	2.0-10.0 %
Basophils	0.3	< 1.0-2.0 %
Method:Microscopy		





Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Req.No : BIL4688733

TID/SID : UMR1943570/ 28215754

Registered on : 09-Sep-2024 / 09:38 AM  $\,$ 

Collected on : 09-Sep-2024 / 09:44 AM

Reported on : 09-Sep-2024 / 13:46 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

Absolute Neutrophil Count Method:Calculated	4115	2000-7000 cells/cumm
Absolute Lymphocyte Count (ALC)	1701	1000-3000 cells/cumm
Absolute Eosinophil Count (AEC)	267	20-500 cells/cumm
Absolute Monocyte Count Method:Calculated	567	200-1000 cells/cumm
Absolute Basophil Count Method:Calculated	20	20-100 cells/cumm
Neutrophil - Lymphocyte Ratio(NLR)  Method:Calculated	2.42	0.78-3.53

Method: Automated Hematology Cell Counter, Microscopy

**Reference:** Dacie and Lewis Practical Hematology,12th Edition. Wallach's interpretation of diagnostic tests, Soth Asian Edition.

**Interpretation:** A Complete Blood Picture (CBP) is a screening test which can aid in the diagnosis of a variety of conditions and diseases such as anemia, leukemia, bleeding disorders and infections. This test is also useful in monitoring a person's reaction to treatment when a condition which affects blood cells has been diagnosed. All the abnormal results are to be correlated clinically.

**Note:** These results are generated by a fully automated hematology analyzer and the differential count is computed from a total of several thousands of cells. Therefore the differential count appears in decimalised numbers and may not add upto exactly 100. It may fall between 99 and 101.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Shruti Reddy Consultant Pathologist Reg No.TSMC/FMR/22656







Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Req.No : BIL4688733

TID/SID : UMR1943570/ 28215756F Registered on : 09-Sep-2024 / 09:38 AM

Collected on : 09-Sep-2024 / 09:44 AM

Reported on : 09-Sep-2024 / 15:09 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

# DEPARTMENT OF CLINICAL CHEMISTRY I Blood Urea Nitrogen (BUN), Serum Investigation Observed Value Biological Reference Interval Blood Urea Nitrogen. 6 6-20 mg/dL Method:Calculated Urea. 11.9 12.8-42.8 mg/dL Method:Urease/UV

**Interpretation:** Urea is a waste product formed in the liver when protein is metabolized. Urea is released by the liver into the blood and is carried to the kidneys, where it is filtered out of the blood and released into the urine. Since this is a continuous process, there is usually a small but stable amount of urea nitrogen in the blood. However, when the kidneys cannot filter wastes out of the blood due to disease or damage, then the level of urea in the blood will rise. The blood urea nitrogen (BUN) evaluates kidney function in a wide range of circumstances, to diagnose kidney disease, and to monitor people with acute or chronic kidney dysfunction or failure. It also may be used to evaluate a person's general health status as well.

Reference: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics

#### Creatinine, Serum

Investigation	Observed Value	Biological Reference Interval
Creatinine.	0.59	0.50-0.90 mg/dL
Method:Alkaline Picrate		

#### Interpretation:

Creatinine is a nitrogenous waste product produced by muscles from creatine. Creatinine is majorly filtered from the blood by the kidneys and released into the urine, so serum creatinine levels are usually a good indicator of kidney function. Serum creatinine is more specific and more sensitive indicator of renal function as compared to BUN because it is produced from muscle at a constant rate and its level in blood is not affected by protein catabolism or other exogenous products. It is also not reabsorbed and very little is secreted by tubules making it a reliable marker. Serum creatinine levels are increased in pre renal, renal and post renal azotemia, active acromegaly and gigantism. Decreased serum creatinine levels are seen in pregnancy and increasing age.

#### Glucose Fasting (FBS), Sodium Fluoride Plasma

Investigation	Observed Value	Biological Reference Interval
Glucose Fasting Method:Hexokinase	95	Normal: <100 mg/dL Impaired FG: 100-125 mg/dL Diabetes mellitus: >/=126 mg/dL

**Interpretation:** It measures the Glucose levels in the blood with a prior fasting of 9-12 hours. The test helps screen a symptomatic/ asymptomatic person who is at risk for Diabetes. It is also used for regular monitoring of glucose levels in people with Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022





Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Reg.No : BIL4688733

TID/SID : UMR1943570/ 28215755 Registered on : 09-Sep-2024 / 09:38 AM

Collected on : 09-Sep-2024 / 09:44 AM

Reported on : 09-Sep-2024 / 15:09 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### Glucose Post Prandial (PPBS), Sodium Fluoride Plasma

Investigation	Observed Value	Biological Reference Interval
Glucose Post Prandial Method:Hexokinase	111	Normal : <140 mg/dL Impaired PG: 140-199 mg/dL Diabetes mellitus: >/=200 mg/dL

**Interpretation:** This test measures the blood sugar levels 2 hours after a normal meal. Abnormally high blood sugars 2 hours after a meal reflect that the body is not producing sufficient insulin which is indicative of Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022

#### Glycosylated Hemoglobin (HbA1C), EDTA Whole Blood

Investigation	Observed Value	Biological Reference Interval
Glycosylated Hemoglobin (HbA1c) Method:High-Performance Liquid Chromatography	5.7	Non-diabetic: <= 5.6 % Pre-diabetic: 5.7 - 6.4 % Diabetic: >= 6.5 %
Estimated Average Glucose (eAG)	117	mg/dL

#### Interpretation:

It is an index of long-term blood glucose concentrations and a measure of the risk for developing microvascular complications in patients with diabetes. Absolute risks of retinopathy and nephropathy are directly proportional to the mean HbA1c concentration. In persons without diabetes, HbA1c is directly related to risk of cardiovascular disease.

- 1) Low glycated haemoglobin (below 4%) in a non-diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency & haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- 2) Interference of Hemoglobinopathies in HbA1c estimation:
- A. For HbF > 25%, an alternate platform (Fructosamine) is recommended for testing of HbA1c.
- B. Homozygous hemoglobinopathy is detected, fructosamine is recommended for monitoring diabetic status
- C. Heterozygous state detected (D10 is corrected for HbS and HbC trait).
- 3) In known diabetic patients, HbA1c can be considered as a tool for monitoring the glycemic control. Excellent Control 6 to 7 %,

Fair to Good Control - 7 to 8 %,

Unsatisfactory Control - 8 to 10 %

and Poor Control - More than 10 %.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022.

#### **Bun/Creatinine Ratio, Serum**

Bull/Creatifile Hatio, Seruili			
Investigation	Observed Val	ue	
BUN/Creatinine Ratio Method:Calculated	8	10-20	_





TO VERIFY THE REPORT ONLINE

Name : MRS.K PAKMODE

Registered on: 09-Sep-2024 / 09:38 AM Age / Gender : 42 Years / Female

Ref.By : SELF

: BIL4688733 Reported on : 09-Sep-2024 / 15:09 PM Reg.No Reference

**TEST REPORT** 

TID/SID

: Arcofemi Health Care Ltd -

Collected on : 09-Sep-2024 / 09:44 AM

: UMR1943570/ 28215755

#### Interpretation:

The BUN/Creatinine ratio blood test is used to diagnose acute or chronic renal disease. BUN (blood urea nitrogen) and creatinine are both filtered in the kidneys and excreted in urine. The two together are used to measure overall kidney function

- 1. Increased ratio (>20) with normal creatinine occurs in the following conditions:
- a) Increased BUN (prerenal azotemia), heart failure, salt depletion, dehydration
- b) Catabolic states with tissue breakdown
- c) GI hemorrhage
- d) Impaired renal function plus excess protein intake, production, or tissue breakdown
- 2. Increased ratio (>20) with elevated creatinine occurs in the following conditions:
- a) Obstruction of urinary tract
- b) Prerenal azotemia with renal disease
- 3. Decreased ratio (<10) with decreased BUN occurs in the following conditions:
- a) Acute tubular necrosis
- b) Decreased urea synthesis as in severe liver disease or starvation
- c) Repeated dialysis
- d) SIADH
- e) Pregnancy
- 4. Decreased ratio (<10) with increased creatinine occurs in the following conditions:
- a) Phenacemide therapy (accelerates conversion of creatine to creatinine)
- b) Rhabdomyolysis (releases muscle creatinine)
- c) Muscular patients who develop renal failure

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---





Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Reg.No : BIL4688733

TID/SID : UMR1943570/ 28215755 Registered on : 09-Sep-2024 / 09:38 AM Collected on : 09-Sep-2024 / 09:44 AM

Reported on : 09-Sep-2024 / 15:09 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Lipid Profile, Serum

Investigation	Observed Value	Biological Reference Interval
Total Cholesterol Method:Cholesterol Oxidase	130	Desirable: <200 mg/dL Borderline: 200-239 mg/dL High: >/=240 mg/dL
HDL Cholesterol Method:Direct Measurement	35	Low: <40 mg/dL High: >/=60 mg/dL
VLDL Cholesterol Method:Calculated	17.00	6.0-38.0 mg/dL
LDL Cholesterol Method:Calculated	78	Optimum: <100 mg/dL Near/above optimum: 100-129 mg/dL Borderline: 130-159 mg/dL High: 160-189 mg/dL Very high: >/=190 mg/dL
Triglycerides Method:Glycerol LPL/GK	85	Normal:<150 mg/dL Borderline: 150-199 mg/dL High: 200-499 mg/dL Very high: >/=500 mg/dL
Chol/HDL Ratio Method:Calculated	3.71	Low Risk: 3.3-4.4 Average Risk: 4.5-7.1 Moderate Risk: 7.2-11.0
LDL Cholesterol/HDL Ratio Method:Calculated	2.23	Desirable: 0.5-3.0 Borderline Risk: 3.0-6.0 High Risk: >6.0

Interpretation: Lipids are fats and fat-like substances which are important constituents of cells and are rich sources of energy. A lipid profile typically includes total cholesterol, high density lipoproteins (HDL), low density lipoprotein (LDL), chylomicrons, triglycerides, very low density lipoproteins (VLDL), Cholesterol/HDL ratio .The lipid profile is used to assess the risk of developing a heart disease and to monitor its treatment. The results of the lipid profile are evaluated along with other known risk factors associated with heart disease to plan and monitor treatment. Treatment options require clinical correlation.

**Reference:** Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2001.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---







Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Req.No : BIL4688733

TID/SID : UMR1943570/ 28215755 Registered on : 09-Sep-2024 / 09:38 AM Collected on : 09-Sep-2024 / 09:44 AM Reported on : 09-Sep-2024 / 15:09 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Liver Function Test (LFT), Serum

Investigation	Observed Value	Biological Reference Interval
Total Bilirubin. Method:Diazo method	0.21	<1.2 mg/dL
Direct Bilirubin. Method:Diazo method	0.12	<0.30 mg/dL
Indirect Bilirubin. Method:Calculated	0.09	<0.9 mg/dL
Alanine Aminotransferase ,(ALT/SGPT) Method:UV wtihout P5P	12	<34 U/L
Aspartate Aminotransferase,(AST/SGOT) Method:UV wtihout P5P	14	<31 U/L
ALP (Alkaline Phosphatase).  Method:PNPP-AMP Buffer	75	35-104 U/L
Gamma GT.  Method:Gamma-Glutamyl - 3 - Carbossi - 4 - Nitroanilide (GCNA)	6	6-42 U/L
Total Protein.  Method:Biuret	7.0	6.6-8.7 g/dL
Albumin. Method:Bromocresol Green (BCG)	4.3	3.5-5.2 g/dL
Globulin. Method:Calculated	2.70	1.8-3.8 g/dL
A/GRatio.  Method:Calculated	1.59	0.8-2.0

**Interpretation:** Liver functions tests help to identify liver disease, its severity, and its type. Generally these tests are performed in combination, are abnormal in liver disease, and the pattern of abnormality is indicative of the nature of liver disease. An isolated abnormality of a single liver function test usually means a non-hepatic cause. If several liver function tests are simultaneously abnormal, then hepatic etiology is likely.

--- End Of Report ---

<sup>\*</sup> Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad







Name : MRS.K PAKMODE
Age / Gender : 42 Years / Female

Ref.By : SELF

Reg.No : BIL4688733

TID/SID : UMR1943570/ 28215755 Registered on : 09-Sep-2024 / 09:38 AM

Collected on : 09-Sep-2024 / 09:44 AM Reported on : 09-Sep-2024 / 13:41 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Thyroid Profile (T3,T4,TSH), Serum

Investigation	Observed Value	Biological Reference Interval
Triiodothyronine Total (T3) Method:ECLIA	1.46	0.80-2.00 ng/mL Pregnancy: 1st Trimester: 0.81 - 1.90 ng/mL 2nd & 3rd Trimester: 1.00 - 2.60 ng/mL
Thyroxine Total (T4) Method:ECLIA	10.1	5.1-14.1 μg/dL
Thyroid Stimulating Hormone (TSH) Method:ECLIA	4.42	0.27-4.20 μIU/mL Pregnancy: 1st Trimester: 0.1 - 2.5 μIU/mL 2nd Trimester: 0.2 - 3.0 μIU/mL 3rd Trimester: 0.3 - 3.0 μIU/mL

Note Kindly correlate clinically

#### Interpretation:

A thyroid profile is used to evaluate thyroid function and/or help diagnose hypothyroidism and hyperthyroidism due to various thyroid disorders. T4 and T3 are hormones produced by the thyroid gland. They help control the rate at which the body uses energy, and are regulated by a feedback system. TSH from the pituitary gland stimulates the production and release of T4 (primarily) and T3 by the thyroid. Most of the T4 and T3 circulate in the blood bound to protein. A small percentage is free (not bound) and is the biologically active form of the hormones.

Reference: Tietz textbook of Clinial Chemistry and Molecular Diagnostics, Nader Rifia, Andrea Ritas Horvath, Carl T. Wittwer.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---







Name : MRS.K PAKMODE

Age / Gender : 42 Years / Female

Ref.By : SELF

Req.No : BIL4688733

Registered on: 09-Sep-2024 / 09:38 AM Collected on: 09-Sep-2024 / 09:44 AM

:UMR1943570/ 28215755

Reported on : 09-Sep-2024 / 15:09 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

	DEPARTMENT OF CLINICAL C	HEMISTRY I
	Uric Acid, Serum	
Investigation	Observed Value	Biological Reference Interval
Uric Acid. Method:Uricase	3.7	2.4-5.7 mg/dL

#### Interpretation

It is the major product of purine catabolism. Hyperuricemia can result due to increased formation or decreased excretion of uric acid which can be due to several causes like metabolic disorders, psoriasis, tissue hypoxia, preeclampsia, alcohol, lead poisoning, acute or chronic kidney disease, etc. Hypouricemia may be seen in severe hepato cellular disease and defective renal tubular reabsorption of uric acid.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---







PLEASE SCAN OR COD

Name: Mrs. K PAKMODE TID: UMR1943570

Age/Gender: 42 Years/FemaleRegistered On: 09-Sep-2024 09:38 AMRef By: SelfReported On: 09-Sep-2024 01:44 PM

Reg.No : BIL4688733 Reference : Arcofemi Health Care Ltd

- Medi Whe

### DEPARTMENT OF MAMMOGRAPHY Mammography Bilateral

Mediolateral oblique and craniocaudal views followed by Sonomammography was performed.

#### **BILATERAL MAMMOGRAPHY:**

Bilateral breasts show fibroglandular fatty tissue (ACR type D), reducing the sentivity of the study.

No evidence of focal soft tissue lesion.

No evidence of cluster microcalcification.

Subcutaneous fat deposition is within normal limits.

Bilateral small volume axillary lymphnodes.

#### **BILATERAL SONOMAMMOGRAPHY:**

Bilateral breasts show dense bilateral fibroglandular parenchyma.

Bilateral symmetrical minimal duct ectasia measuring 1.4 mm. No intraluminal lesions.

Few scattered bilateral simple cysts, largest measuring  $5.7 \times 2.9$  mm in left breast.

#### **IMPRESSION:**

- \* Bilateral symmetrical minimal duct ectasia measuring 1.4 mm. No intraluminal lesions Benign BIRADS 2.
- \* Bilateral simple breast cysts BIRADS 2.





PLEASE SCAN OR CODE

Name : Mrs . K PAKMODE	TID	: UMR1943570
------------------------	-----	--------------

Age/Gender: 42 Years/FemaleRegistered On: 09-Sep-2024 09:38 AMRef By: SelfReported On: 09-Sep-2024 01:44 PMReg.No: BIL4688733Reference: Arcofemi Health Care Ltd

- Medi Whe

#### **BI-RADS CLASSIFICATION**

CATEGORY	RESULT
0	Assessment incomplete. Need additional imaging evaluation
1	Negative. Routine mammogram in 1 year recommended.
2	Benign finding. Routine mammogram in 1 year recommended.
3	Probably benign finding. Short interval follow-up suggested.
4	Suspicious - 4A: Low suspicion for malignancy (2 - 9%) 4B: Moderate suspicion for malignancy (10 - 49%) 4C: High suspicion for malignancy (50 - 94%)
	Biopsy should be considered.
5 taken.	Highly suggestive of malignancy. Appropriate action should be
6.	Known biopsy proven malignancy.

- Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

**Dr. Apoorva K**Consultant Radiologist





TO VERIFY THE REPORT ONLINE

Name : MRS.K PAKMODE

: 42 Years / Female Age / Gender

Ref.By : SELF

: BIL4688733 Req.No

:UMR1943570/ 28222678 Registered on: 09-Sep-2024 / 09:38 AM Collected on : 10-Sep-2024 / 10:46 AM

Reported on : 11-Sep-2024 / 16:44 PM

Reference : Arcofemi Health Care Ltd -**TEST REPORT** 

#### **DEPARTMENT OF CYTOPATHOLOGY**

#### Pap Smear, Conventional

Cytology No C-9603/24

Clinical Details For screening.

Specimen Type Conventional smear (Pap smear)

Specimen Adequacy Satisfactory for evaluation without evidence of

endocervical/transformation zone component

TID/SID

Microscopic Observations: Smear contains superficial, intermediate cells. Scant inflammation

noted.

Organisms Not present

Interpretation Negative for intraepithelial lesion or malignancy.


Method: Pap staining & microscopy

Reported as per the 2014 Bethesda System

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Shruti Reddy **Consultant Pathologist** Reg No.TSMC/FMR/22656



K PAKMODE BIL4688733 22691306 MAMMOGRAM 9/9/2024 TENET DIAGNOSTICS GACHIBOWLI HYD

### GACHIBOWLI, HYDERABAD. TENET MEDCORP PVT LTD

46887337K PAKMODE 42 Yrs/Female 75 Kg/155 Cms Date: 09-Sep-2024 10:19:55 AM

Ref. By : ARCOFEMI HEALTH CARE

Medication: Nit Objective:

Summary

Protocol : BRUCE History : Nil


1 3:01 3:02 2.7 10.0 4.6 162 140/80 226 .  x 2:38 5:39 4.0 12.0 6.7 177 150/80 265 .  ery 1:00 0.0 0.0 1.0 147 160/80 235 .  gs :  Exercise Time : 5:38 minutes  Max HR attained : 177 bpm 99% of Max Predictable HR 178  Max BP : 160/80(mmHig)  WorkLoad attained : 6.7 (Fair Effort Tolerance)  No significant ST segment changes noted during exercise or recovery.  No Angina / Arrhythmia / SOB  Final Impression:*** TEST IS NEGATIVE FOR EXERCISE INDUCIBLE SICHEMIA****  Properties By DR INDRANLT  SP. Rajesh Karroharia  Live St. PG DIP CARB (London)
2.7 10.0 4.6 162 140/80 4.0 12.0 6.7 177 150/80 0.0 0.0 1.0 147 160/80 0.0 0.0 1.0 97 130/80 ppm 99% of Max Predictable HR 178 air Effort Tolerance) hanges noted during exercise or recovery.  NEGATIVE FOR EXERCISE INDUCIBLE SICHEMIA***  PG DIP CARD (London)  Oclass Carstologist
102 · 226 · · 235 · · 126 · · · · · · · · · · · · · · · · · · ·
V2  V2  PreEx  Presc  P
ave ave with the winds of the state of the s

42 Yrs/Female 75 Kg/155 Cms Date: 09-Sep-2024 10:19:55 AM 4688733/K PAKMODE

HR: 78 bpm METS: 1.0 BP: 120/80 Stage Report Time: 09-Sep-2024 10:21:40 AM MPHR:43% of 178 Speed: 0.0 kmph Grade: 0.0%

BRUCE (0.05-190)Hz

Ex Time 01:34 BLC :On Notch :On SUPINE 10.0 mm/mV 25 mm/Sec.



# GACHIBOWLI, HYDERABAD. TENET MEDCORP PYT LTD


4688733/K PAKMODE 42 Yrs/Female 75 Kg/155 Cms Date: 09-Sep-2024 10:19:55 AM

BRUCE (0.05-100)Hz

Linked Medians Report

Ex Time 01:36 BLC :On Notch :On

STANDING 10.0 mm/mY 25 mm/Sec.



## GACHIBOWLI, HYDERABAD. TENET MEDCORP PVT LTD

42 Yrs/Female 46887337K PAKMODE


75 Kg/155 Cms Date: 09-Sep-2024 10:19:55 AM

BRUCE (0.05-100)Hz

Linked Medians Report

Ex Time 00:00 BLC :On Notch :On

ExStart 10.0 mm/mV 25 mm/Sec.




75 Kg/155 Cms Date: 09-Sep-2024 10:19:55 AM


42 Yrs/Female

IPHR:91% of 178 BRUCE peed: 2.7 kmph (0.05-100)Hz rade: 10.0%

Ex Time 03:00 BLC :On Notch :On

Stage 1 (03:00) 10.0 mm/mV 25 mm/Sec.





0.1

Date: 09-Sep-2024 10:19:55 AM 42 Yrs/Female 75 Kg/155 Cms 46887337K PAKMODE


Stage Report Time: 09-Sep-2024 10:27:49 AM BP: 150/80 HR: 177 bpm Grade: 12.0% Speed: 4.0 kmph MPHR:99% of 178

METS: 6.7

(0.05-100)Hz

Ex Time 05:37 BLC :On Notch :On

10.0 mm/mV 25 mm/Sec. PeakEx



# GACHIBOWLI, HYDERABAD. TENET MEDCORP PYT LTD

75 Kg/155 Cms Date: 09-Sep-2024 10:19:55 AM 42 Yrs/Female 46887337K PAKMODE

BP: 150/80 METS: 2.1 HR: 170 bpm


Stage Report Time: 09-Sep-2024 10:28:14 AM Grade: 0.0% Speed: 1.8 kmph MPHR:95% of 178

(0.05-100)Hz

Linked Medians Report

Ex Time 05:37 BLC :On Notch:On

Recovery: (00:24) 10.0 mm/mV 25 mm/Sec.



### GACHIBOWLI, HYDERABAD. TENET MEDCORP PVT LTD

4688733/K PAKMODE 75 Kg/155 Cms 42 Yrs/Female

Date: 09-Sep-2024 10:19:55 AM


HR; 147 bpm METS; 1,0 BP: 160/80


BRUCE (0.05-100)Hz


Linked Medians Report

Ex Time 05:37 BLC :On Notch :On

Recovery: (00:59) 10.0 mm/mV 25 mm/Sec.











DI FASE SCAN OR CODI

Name : Mrs. K PAKMODE TID : UMR1943570

Age/Gender: 42 Years/FemaleRegistered On: 09-Sep-2024 09:38 AMRef By: SelfReported On: 09-Sep-2024 01:38 PM

Reg.No : BIL4688733 Reference : Arcofemi Health Care Ltd

- Medi Whe

### DEPARTMENT OF ULTRASOUND **Ultrasound Whole Abdomen**

**LIVER** is normal shape, size (13.8 cms) and has uniform echopattern. No evidence of focal lesion. No intrahepatic biliary ductal dilatation. Hepatic and portal vein radicals are normal.

**GALL BLADDER** shows normal shape and has clear contents. Gall bladder wall is of normal thickness. CBD is of normal calibre.

**PANCREAS** has normal shape, size and uniform echopattern. No evidence of ductal dilatation or calcification.

**SPLEEN** shows normal shape, size (9.3 cms) and echopattern.

**KIDNEYS** move well with respiration and have normal shape, size and echopattern. Cortico- medullary differentiations are well madeout. No evidence of calculus or hydronephrosis.

Right kidney measures :  $10.1 \times 3.8 \text{ cms}$ , Left kidney measures :  $10.6 \times 4.7 \text{ cms}$ .

**URINARY BLADDER** shows normal shape and wall thickness. It has clear contents. No evidence of diverticula.

**UTERUS** is anteverted has normal shape and size.

It has uniform myometrial echopattern.

Endometrial echo is of normal thickness: 5.7 mm.

Uterus measures: 9.4 x 4.9 x 5.6 cms.

**OVARIES** are normal in size, shape and echotexture. Right ovary: 2.5 x 1.7 cms, Left ovary: 3.4 x 1.3 cms.

No evidence of free fluid in the abdomen and pelvis.





PLEASE SCAN OR CODE

Name : Mrs . K PAKMODE TID : UMR1943570

Age/Gender: 42 Years/FemaleRegistered On: 09-Sep-2024 09:38 AMRef By: SelfReported On: 09-Sep-2024 01:38 PM

Ref By: SelfReported On: 09-Sep-2024 01:38 PMReg.No: BIL4688733Reference: Arcofemi Health Care Ltd

- Medi Whe

#### **IMPRESSION:**

#### \* NO SONOGRAPHIC ABNORMALITY DETECTED.

- Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

**Dr. Apoorva K**Consultant Radiologist





PLEASE SCAN OR CODE

Name : Mrs. K PAKMODE TID : UMR1943570

Age/Gender: 42 Years/FemaleRegistered On: 09-Sep-2024 09:38 AMRef By: SelfReported On: 09-Sep-2024 03:47 PM

Reg.No : BIL4688733 Reference : Arcofemi Health Care Ltd

- Medi Whe

### DEPARTMENT OF X-RAY X-Ray Chest PA View

**CLINICAL DETAILS:** Health checkup.

#### **FINDINGS:**

Lung fields appear normal.

Cardiac size is within normal limits.

Aorta and pulmonary vasculature is normal.

Bilateral domes of diaphragm and costophrenic angles are normal.

Visualised bones and soft tissues appear normal.

#### **IMPRESSION:**

#### \* NORMAL STUDY.

- Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

**Dr. Apoorva K**Consultant Radiologist

